The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

<p><strong>Background:</strong> The mutational landscape of SARS-CoV-2 varies at the dominant viral genome sequence and minor genomic variant population. During the COVID-19 pandemic, an early substitution in the genome was the D614G change in the spike protein, associated with an...

Täydet tiedot

Bibliografiset tiedot
Päätekijät:	Goldswain, H, Dong, X, Penrice-Randal, R, Alruwaili, M, Shawli, GT, Prince, T, Williamson, MK, Raghwani, J, Randle, N, Jones, B, Donovan-Banfield, I, Salguero, FJ, Tree, JA, Hall, Y, Hartley, C, Erdmann, M, Bazire, J, Jearanaiwitayakul, T, Semple, MG, Openshaw, PJM, Baillie, JK, Emmett, SR, Digard, P, Matthews, DA, Turtle, L, Darby, AC, Davidson, AD, Carroll, MW, Hiscox, JA, Carson, G, Dunning, J, Horby, PW, Klenerman, P, Mentzer, AJ, Merson, L, Sigfrid, L, Stuart, D, Angus, B
Muut tekijät:	ISARIC4C Investigators
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	BioMed Central 2023

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

Samankaltaisia teoksia